Internet Explorer is no longer supported by Microsoft. To browse the NIHR site please use a modern, secure browser like Google Chrome, Mozilla Firefox, or Microsoft Edge.

Excess Treatment Costs (ETCs) related to COVID-19 studies


17 July 2020


1.0 July 2020


Guidance from NHS England and Improvement:

All COVID-19 studies, including studies categorised as Urgent Public Health Research (UPH) studies, should continue to adhere to the standard processes and mechanism for Excess Treatment Cost (ETC) attribution, costing and validation by completing a Schedule of Events Cost Attribution Template (SOECAT) as per usual practice. 

ETC payments for these studies will also be made in accordance with the arrangements of the national ETC system. 

For studies where CCGs are the responsible commissioner, ETC payments for COVID-19 studies will be subject to provider thresholds where applicable.  

Due to the disruption arising from COVID-19, as well as enhancements that we are making to the payments process, all CCG Excess Treatment Cost (ETC) payments made by NIHR Local Clinical Research Networks (LCRNs) will be suspended until at least Quarter 2 of the financial year 2020/21. Note: This includes payments to both primary and secondary care providers.

For studies where NHS England and Improvement Specialised Commissioning is the responsible commissioner, ETC payments will be subject to specialised commissioning national finance team’s assurance review, and will take into consideration block funding arrangements that are in place to support funding flows during the COVID-19 pandemic.